<DOC>
	<DOCNO>NCT01917006</DOCNO>
	<brief_summary>This safety efficacy study BOTOX® ( onabotulinumtoxinA ) treatment premature ejaculation male patient .</brief_summary>
	<brief_title>A Safety Efficacy Study BOTOX® Premature Ejaculation</brief_title>
	<detailed_description>This phase 2 , multicenter , randomize , double-blind , placebo-controlled , dose-escalation study ass range dose BOTOX treatment male patient PE . Patients attend minimum 6 7 clinic visit also 1 2 telephone visit . Partners need attend clinic visit screen period provide inform consent receive training measurement record IELT . Patients enrol cohort . Within first 5 cohort , 8 patient receive BOTOX 2 patient receive placebo . For cohort 6 , 12 patient receive BOTOX 12 patient receive placebo . Patients receive single treatment study medication deliver bilaterally bulbospongiosus muscle . The initial BOTOX total dose dose escalation study 5 U maximum BOTOX total dose 100 U . Upon request eligible , patient cohort 6 , option receive second injection BOTOX ( open label ) .</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Premature Ejaculation</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>History premature ejaculation Stable monogamous sexual relationship female partner least 6 month , intend continue partner duration study Patient ability follow study instruction complete study assessment tool Premature ejaculation cause medical surgical issue , related stress issue ( eg , relationship problem ) Pain ejaculation Planned use topical penile treatment ( eg , anesthetic , herbal treatment ) penile injection study Prior genital , prostatic low urinary tract surgery ( vasectomy circumcision ) Previous current usage botulinum toxin therapy serotype urological condition Use botulinum toxin therapy serotype nonurological condition ( eg , cosmetic , chronic migraine ) 12 week prior screen , plan usage study Diagnosis Myasthenia gravis , Eaton‐Lambert Syndrome , Amyotrophic Lateral Sclerosis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>